Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant

• Published in: Journal of clinical oncology Vol. 40; no. 33; pp. 3808 - 3816
• Main Authors: Valanparambil, Rajesh M., Carlisle, Jennifer, Linderman, Susanne L., Akthar, Akil, Millett, Ralph Linwood, Lai, Lilin, Chang, Andres, McCook-Veal, Ashley A., Switchenko, Jeffrey, Nasti, Tahseen H., Saini, Manpreet, Wieland, Andreas, Manning, Kelly E., Ellis, Madison, Moore, Kathryn M., Foster, Stephanie L., Floyd, Katharine, Davis-Gardner, Meredith E., Edara, Venkata-Viswanadh, Patel, Mit, Steur, Conor, Nooka, Ajay K., Green, Felicia, Johns, Margaret A., O'Brein, Fiona, Shanmugasundaram, Uma, Zarnitsyna, Veronika I., Ahmed, Hasan, Nyhoff, Lindsay E., Mantus, Grace, Garett, Michael, Edupuganti, Srilatha, Behra, Madhusmita, Antia, Rustom, Wrammert, Jens, Suthar, Mehul S., Dhodapkar, Madhav V., Ramalingam, Suresh, Ahmed, Rafi
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 20.11.2022
• Subjects: Aged; Antibodies, Neutralizing; Antibodies, Viral; Antibody Formation; Carcinoma, Non-Small-Cell Lung - therapy; COVID-19 - prevention & control; COVID-19 Vaccines; Humans; Immunization; Lung Neoplasms - therapy; mRNA Vaccines; RNA, Messenger; SARS-CoV-2; Vaccination
• ISSN: 0732-183X; 1527-7755; 1527-7755
• DOI: 10.1200/JCO.21.02986

PURPOSETo examine COVID-19 mRNA vaccine-induced binding and neutralizing antibody responses in patients with non-small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after the primary 2-dose and booster vaccination.METHODSEighty-two patients with NSCLC and 53 healthy volunteers who received SARS-CoV-2 mRNA vaccines were included in the study. Blood was collected longitudinally, and SARS-CoV-2-specific binding and neutralizing antibody responses were evaluated by Meso Scale Discovery assay and live virus Focus Reduction Neutralization Assay, respectively.RESULTSA majority of patients with NSCLC generated binding and neutralizing antibody titers comparable with the healthy vaccinees after mRNA vaccination, but a subset of patients with NSCLC (25%) made poor responses, resulting in overall lower (six- to seven-fold) titers compared with the healthy cohort (P = < .0001). Although patients age > 70 years had lower immunoglobulin G titers (P = < .01), patients receiving programmed death-1 monotherapy, chemotherapy, or a combination of both did not have a significant impact on the antibody response. Neutralizing antibody titers to the B.1.617.2 (Delta), B.1.351 (Beta), and in particular, B.1.1.529 (Omicron) variants were significantly lower (P = < .0001) compared with the 614D (WT) strain. Booster vaccination led to a significant increase (P = .0001) in the binding and neutralizing antibody titers to the WT and Omicron variant. However, 2-4 months after the booster, we observed a five- to seven-fold decrease in neutralizing titers to WT and Omicron viruses.CONCLUSIONA subset of patients with NSCLC responded poorly to the SARS-CoV-2 mRNA vaccination and had low neutralizing antibodies to the B.1.1.529 Omicron variant. Booster vaccination increased binding and neutralizing antibody titers to Omicron, but antibody titers declined after 3 months. These data highlight the concern for patients with cancer given the rapid spread of SARS-CoV-2 Omicron variant.